SkinBioTherapeutics narrows losses, forecasts 2026 growth
Newcastle's SkinBioTherapeutics reports soaring revenue and reduced losses, driven by its AxisBiotix range and a major new deal with Superdrug. The firm anticipates significant growth in 2026.